For example, colon and kidney cancers have been shown to express high levels of P-gp, while ovary, breast, melanomas, lymphomas, lung, and multiple myelomas cancers express low levels of P-gp, even though P-gp expression elevates upon acquired drug resistance. Here, PGP is linked to melanoma.